Danaher

Danaher is a leading global innovator in life sciences and diagnostics, dedicated to accelerating the power of science and technology to improve human health. The company’s Biotechnology business, led by Cytiva, provides expertise, technologies, and services that accelerate the development and commercialization of life-changing therapies. Danaher’s Diagnostics businesses create tools and software designed to improve confidence in precise and rapid diagnoses, operating across six continents and harnessing digital data for precision diagnostics. The Life Sciences segment powers tools and technologies that support customers in creating breakthrough cell and gene therapies and driving advances in molecular oncology. Guided by the Danaher Business System (DBS), the company maintains a culture of performance and continuous improvement. Danaher employs a focused acquisition strategy to enhance its technological capabilities and collaborates with top academic researchers to advance R&D and create breakthrough technologies. With a global presence and headquarters in Washington, DC, Danaher emphasizes sustainability, diversity, equity, and inclusion. The company has achieved pay equity in the U.S. since 2020 and promotes diversity through several Associate Resource Groups (ARGs). Danaher’s Beacons program partners with leading academics to drive transformational change. Notable projects include developing a blood test for Alzheimer’s disease with improved sensitivity and a new system by Beckman Coulter that offers 100 times the sensitivity of previous immunoassay platforms. Danaher’s businesses support revolutionary innovations, including enhanced synthetic biologics and gene and cell therapies, while the company’s sustainability strategy focuses on innovating products that improve lives and protect the environment.